Literature DB >> 10741625

Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers.

U Hollenstein1, M Brunner, B X Mayer, S Delacher, B Erovic, H G Eichler, M Müller.   

Abstract

BACKGROUND: Recent data indicate a higher level of effectivity of beta-lactam antibiotics if serum concentrations are kept above the minimal inhibitory concentration (MIC) of the pathogen. This concept would favor continuous infusion over bolus dosing. However, it is usually not the serum concentration but the free interstitial concentration in the target tissue that determines antibiotic activity. We therefore set out to measure effective drug concentrations in the interstitial space of muscle and subcutaneous adipose tissue and to compare trough levels and times above the MIC after bolus versus continuous infusion of cefpirome.
METHODS: Twelve healthy volunteers received a single dose of 2 g cefpirome as an intravenous bolus or as a continuous infusion over 8 hours in a crossover design, and the resulting free interstitial tissue concentrations were measured with use of microdialysis.
RESULTS: After bolus injection, mean interstitial trough concentrations were 3.0 +/- 1.9 microg/mL and 2.1 +/-1.0 microg/mL for muscle and subcutaneous tissue, respectively; continuous infusion resulted in trough levels of 10.1 +/- 6.8 microg/mL and 10.1 +/- 4.6 microg/mL for muscle and subcutaneous tissue, respectively. This resulted in significantly longer times above the MIC with continuous infusion for Staphylococcus epidermidis and Enterobacter cloacae. Bacteria with an MIC < or =1 would be covered by either method, whereas higher doses seem to be necessary for Pseudomonas aeruginosa.
CONCLUSION: Although susceptible organisms will usually be covered sufficiently with standard dosing regimens, soft tissue infections with bacteria that have MIC values of 2 to 8 may profit from continuous application. Coverage of P aeruginosa, however, would be inadequate with conventional daily doses of 4 g cefpirome regardless of the method of application.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741625     DOI: 10.1067/mcp.2000.104266

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Perioperative penetration of metronidazole into muscle tissue: a microdialysis study.

Authors:  Juri Karjagin; Rein Pähkla; Joel Starkopf
Journal:  Eur J Clin Pharmacol       Date:  2003-10-29       Impact factor: 2.953

Review 3.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 4.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.

Authors:  Sofia K Kasiakou; Kenneth R Lawrence; Nicolaos Choulis; Matthew E Falagas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 7.  Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization.

Authors:  Amelia N Deitchman; M Tobias Heinrichs; Vipada Khaowroongrueng; Satyawan B Jadhav; Hartmut Derendorf
Journal:  AAPS J       Date:  2016-12-09       Impact factor: 4.009

8.  Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.

Authors:  Robert Sauermann; Georg Delle-Karth; Claudia Marsik; Ilka Steiner; Markus Zeitlinger; Bernhard X Mayer-Helm; Apostolos Georgopoulos; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

9.  Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.

Authors:  April Barbour; Stephan Schmidt; Sreedharan Nair Sabarinath; Maria Grant; Christoph Seubert; Donna Skee; Bindu Murthy; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.